<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20130304012695N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-07-04</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of bicarbonate in increasing blood pressure in patients with hemorrhagic shock</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of hemodynamic effects of bicarbonate infusion in hemorrhagic shock</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/48508</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: To randomize patients with inclusion criteria 
   Block balanced randomization is used.Before studying, one of the person who is not a member of the research team performs the randomization process  by  using Random generator software, forms four blocks for the intervention and control group.
The complete cards of the four blocks are given to the head of the operating room, who is unaware of the study, in an envelope. A card is given to the patient after patient entrance to operating room, Blinding description: The patient is unaware of the type of intervention.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Condition 1: hemorrhagic shock. Condition 2: Acidosis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients who has blood loss more than 500 cc during surgery within 20 minutes and have a systolic blood pressure less  than 100 mm Hg, sodium  bicarbonate infusion started at a rate of 5 cc / minute intravenously and continue until the systolic blood pressure reaches 100 mm Hg,then reduce the rate of bicarbonate  to 2 cc/ minute.If the bleeding increases to the tolerable limit level , in each patient transfusion is started .At the end of the transfusion and stop the bleeding, a blood sample is sent to measure blood gases and lactic acid in the blood. Intervention 2: Control group: Patients who has blood loss more than 500 cc during surgery within 20 minutes and have a systolic blood pressure less  than 100 mm Hg, Serum Ringer infusion starts at 15 ml / min.  If the pressure does not rise after 10 minutes, the Nor adrenaline infusion begins.If the bleeding increases to the tolerable limit level in each patient, transfusion will start .At the end of the transfusion and stop the bleeding, a blood sample is sent to measure blood gases and lactic acid in the blood.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All information used for this research can be shared after unidentified the identity of patients. Also, statistical information, information analysis, study method, findings and conclusions can be shared.

When:
Starting access after accepting by a valid scientific journal and publishing it

To whom:
For academic researchers and in the field of science

Conditions:
All researchers can use all published material and if all or part of this research is published by other people, the name and source of this research and its researchers should be mentioned.

Where to obtain:
Dr. Mohammad Reza Khajavi Email: khajavim@tums.ac.ir

How to obtain:
The applicant can request the type of files by email.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammadreza Khajavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sina hospital Imam Khomeini st.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1136746911</zip>
        <telephone>+98 21 6312 1220</telephone>
        <email>khajavim@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Reza Khajavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sina hospital, Imam khomeni St</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1136746911</zip>
        <telephone>+98 21 6312 0000</telephone>
        <email>KHAGAVIM@TUMS.AC.IR</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All patients whose bleeding is more than 500 cc
systolic blood pressure lower than 100 mm
patients with ASA I,II,III who are candidates for orthopedic Hip surgery, neurosurgery, and vascular surgery.
patients required to receive blood transfusions,
patients with hemorrhagic shock</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>All patients with liver dysfunction
lung disorders such as COPD
increased ICP
Patients who do not agree to participate in this study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R57.1</hc_code>
      <hc_code>E87.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Hypovolemic shock</hc_keyword>
      <hc_keyword>Acidosis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients who has blood loss more than 500 cc during surgery within 20 minutes and have a systolic blood pressure less  than 100 mm Hg, sodium  bicarbonate infusion started at a rate of 5 cc / minute intravenously and continue until the systolic blood pressure reaches 100 mm Hg,then reduce the rate of bicarbonate  to 2 cc/ minute.If the bleeding increases to the tolerable limit level , in each patient transfusion is started .At the end of the transfusion and stop the bleeding, a blood sample is sent to measure blood gases and lactic acid in the blood.</i_keyword>
      <i_keyword>Control group: Patients who has blood loss more than 500 cc during surgery within 20 minutes and have a systolic blood pressure less  than 100 mm Hg, Serum Ringer infusion starts at 15 ml / min.  If the pressure does not rise after 10 minutes, the Nor adrenaline infusion begins.If the bleeding increases to the tolerable limit level in each patient, transfusion will start .At the end of the transfusion and stop the bleeding, a blood sample is sent to measure blood gases and lactic acid in the blood.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Lactic Acidosis. Timepoint: At the end of surgery. Method of measurement: Vein blood sample mg/dl.</prim_outcome>
      <prim_outcome>Blood pressure changes. Timepoint: After the start of bicarbonate or serum at minutes 3-6-9 12-15. Method of measurement: Through the artier line with Lidco device /mmgh.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Blood acidosis. Timepoint: At the end of transfusion. Method of measurement: Arterial blood sample.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-06-11</approval_date>
        <contact_name>Ethics committee of ،Tehran University of Medical Sciences</contact_name>
        <contact_address>SinaHospital, ImamKhomeini st. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
